- Home
- REE vs COCP Comparison
REE vs COCP Comparison
Compare REE & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REE | COCP |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 15.6M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | REE | COCP |
|---|---|---|
| Price | $0.43 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 78.4K | ★ 122.4K |
| Earning Date | 06-16-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.86 |
| 52 Week High | $1.76 | $2.19 |
Technical Indicators
Market Signals| Indicator | REE | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 37.15 |
| Support Level | $0.33 | $1.00 |
| Resistance Level | $0.49 | $1.11 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 56.81 | 14.71 |
Price Performance
Historical ComparisonAbout REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).